Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
Tóm tắt
Từ khóa
Tài liệu tham khảo
Qian, 2010, Macrophage diversity enhances tumor progression and metastasis, Cell, 141, 39, 10.1016/j.cell.2010.03.014
Belli, 2018, Targeting the microenvironment in solid tumors, Cancer Treat Rev, 65, 22, 10.1016/j.ctrv.2018.02.004
Noy, 2014, Tumor-associated macrophages: from mechanisms to therapy, Immunity, 41, 49, 10.1016/j.immuni.2014.06.010
Xu, 2015, Intratumoral delivery of IL-21 overcomes anti-Her2/Neu resistance through shifting tumor-associated macrophages from M2 to M1 phenotype, J Immunol, 194, 4997, 10.4049/jimmunol.1402603
DeNardo, 2011, Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy, Cancer Discov, 1, 54, 10.1158/2159-8274.CD-10-0028
Shiao, 2015, TH2-polarized CD4(+) T cells and macrophages limit efficacy of radiotherapy, Cancer Immunol Res, 3, 518, 10.1158/2326-6066.CIR-14-0232
Zhang, 2012, Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature, PLoS One, 7, e50946, 10.1371/journal.pone.0050946
Altman, 2012, Reporting recommendations for tumor marker prognostic studies (REMARK):explanation and elaboration, PLoS Med, 9, e1001216, 10.1371/journal.pmed.1001216
Bain, 2013, Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6C hi monocyte precursors, Mucosal Immunol, 6, 498, 10.1038/mi.2012.89
Mantovani, 2017, Tumour-associated macrophages as treatment targets in oncology, Nat Rev Clin Oncol, 14, 399, 10.1038/nrclinonc.2016.217
Pollard, 2008, Macrophages define the invasive microenvironment in breast cancer, J Leukoc Biol, 84, 623, 10.1189/jlb.1107762
Franklin, 2014, The cellular and molecular origin of tumor-associated macrophages, Science, 344, 921, 10.1126/science.1252510
Martinez, 2006, Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression, J Immunol, 177, 7303, 10.4049/jimmunol.177.10.7303
Mosser, 2008, Exploring the full spectrum of macrophage activation, Nat Rev Immunol, 8, 958, 10.1038/nri2448
Mantovani, 2002, Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes, Trends Immunol, 23, 549, 10.1016/S1471-4906(02)02302-5
Biswas, 2010, Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm, Nat Immunol, 11, 889, 10.1038/ni.1937
Martinez, 2014, The M1 and M2 paradigm of macrophage activation: time for reassessment, F1000Prime Rep, 6, 13, 10.12703/P6-13
Aras, 2017, TAMeless traitors: macrophages in cancer progression and metastasis, Br J Cancer, 117, 1583, 10.1038/bjc.2017.356
Sousa, 2015, Human breast cancer cells educate macrophages toward the M2 activation status, Breast Cancer Res, 17, 101, 10.1186/s13058-015-0621-0
Su, 2014, A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis, Cancer Cell, 25, 605, 10.1016/j.ccr.2014.03.021
Ruffell, 2015, Macrophages and therapeutic resistance in cancer, Cancer Cell, 27, 462, 10.1016/j.ccell.2015.02.015
Mahmoud, 2012, Tumour-infiltrating macrophages and clinical outcome in breast cancer, J Clin Pathol, 65, 159, 10.1136/jclinpath-2011-200355
Yuan, 2014, High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis, Onco Targets Ther, 7, 1475, 10.2147/OTT.S61838
Tiainen, 2015, High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer, Histopathology, 66, 873, 10.1111/his.12607
Liu, 2017, Jagged1 modulated tumor-associated macrophage differentiation predicts poor prognosis in patients with invasive micropapillary carcinoma of the breast, Med, 96, e6663, 10.1097/MD.0000000000006663
Gwak, 2015, Prognostic value of tumor-associated macrophages according to histologic locations and hormone receptor status in breast cancer, PLoS One, 10, 1, 10.1371/journal.pone.0125728
Mohammed, 2012, The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer, Br J Cancer, 107, 864, 10.1038/bjc.2012.347
Zhang, 2018, Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients, J Surg Res, 222, 93, 10.1016/j.jss.2017.09.035
Klingen, 2017, Tumor-associated macrophages are strongly related to vascular invasion, non-luminal subtypes, and interval breast cancer, Hum Pathol, 69, 72, 10.1016/j.humpath.2017.09.001
Ali, 2016, Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study, PLoS Med, 13, e1002194, 10.1371/journal.pmed.1002194
Bense, 2017, Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer, J Natl Cancer Inst, 109, 1, 10.1093/jnci/djw192
Gottfried, 2008, Expression of CD68 in non-myeloid cell types, Scand J Immunol, 67, 453, 10.1111/j.1365-3083.2008.02091.x
Ambarus, 2012, Systematic validation of specific phenotypic markers for in vitro polarized human macrophages, J Immunol Methods, 375, 196, 10.1016/j.jim.2011.10.013
Georgoudaki, 2016, Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis, Cell Rep, 15, 2000, 10.1016/j.celrep.2016.04.084
Koru-Sengul, 2016, Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians, Breast Cancer Res Treat, 158, 113, 10.1007/s10549-016-3847-3
Miyasato, 2017, The high density of CD204-positive macrophages predicts worse clinical prognosis in patients with breast cancer, Cancer Sci, 108, 1693, 10.1111/cas.13287
Yuan, 2017, Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis, Gynecol Oncol, 147, 181, 10.1016/j.ygyno.2017.07.007
Carron, 2017, Macrophages promote the progression of premalignant mammary lesions to invasive cancer, Oncotarget, 8, 50731, 10.18632/oncotarget.14913
Aharinejad, 2004, Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice, Cancer Res, 64, 5378, 10.1158/0008-5472.CAN-04-0961
Germano, 2013, Role of macrophage targeting in the antitumor activity of trabectedin, Cancer Cell, 23, 249, 10.1016/j.ccr.2013.01.008
Li, 2015, Cyclooxygenase-2 in tumor-associated macrophages promotes breast cancer cell survival by triggering a positive-feedback loop between macrophages and cancer cells, Oncotarget, 6, 29637, 10.18632/oncotarget.4936
Muthuswamy, 2017, Epinephrine promotes COX-2-dependent immune suppression in myeloid cells and cancer tissues, Brain Behav Immun, 62, 78, 10.1016/j.bbi.2017.02.008
Sangaletti, 2008, Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis, Cancer Res, 68, 9050, 10.1158/0008-5472.CAN-08-1327
Chen, 2011, CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3, Cancer Cell, 19, 541, 10.1016/j.ccr.2011.02.006
Wyckoff, 2004, A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors, Cancer Res, 64, 7022, 10.1158/0008-5472.CAN-04-1449
Su, 2017, Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer, Cell Res, 27, 461, 10.1038/cr.2017.34
Trikha, 2016, E2f3 in tumor macrophages promotes lung metastasis, Oncogene, 35, 3636, 10.1038/onc.2015.429
Harney, 2015, Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage–derived VEGFA, Cancer Discov, 5, 932, 10.1158/2159-8290.CD-15-0012
Harney, 2017, The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2Hi macrophages in breast cancer and pancreatic neuroendocrine tumors, Mol Cancer Ther, 16, 2486, 10.1158/1535-7163.MCT-17-0241
Mazzieri, 2011, Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells, Cancer Cell, 19, 512, 10.1016/j.ccr.2011.02.005
Linde, 2018, Macrophages orchestrate breast cancer early dissemination and metastasis, Nat Commun, 9, 21, 10.1038/s41467-017-02481-5
Qian, 2009, A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth, PLoS ONE, 4, e6562, 10.1371/journal.pone.0006562
Qian, 2011, CCL2 recruits inflammatory monocytes to facilitate breast tumour metastasis, Nature, 475, 222, 10.1038/nature10138
Kitamura, 2015, CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages, J Exp Med, 212, 1043, 10.1084/jem.20141836
Kersten, 2017, Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages, Oncoimmunology, 6, e1334744, 10.1080/2162402X.2017.1334744
Qian, 2015, FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis, J Exp Med, 212, 1433, 10.1084/jem.20141555
Mathsyaraja, 2015, CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth, Oncogene, 34, 3651, 10.1038/onc.2014.294
Mantovani, 2015, The interaction of anticancer therapies with tumor-associated macrophages, J Exp Med, 212, 435, 10.1084/jem.20150295
Shree, 2011, Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer, Genes Dev, 25, 2465, 10.1101/gad.180331.111
Olson, 2017, Tumor-associated macrophages suppress the cytotoxic activity of antimitotic agents, Cell Rep, 19, 101, 10.1016/j.celrep.2017.03.038
Paulus, 2006, Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts, Cancer Res, 66, 4349, 10.1158/0008-5472.CAN-05-3523
Yang, 2015, Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway, Med Oncol, 32, 352, 10.1007/s12032-014-0352-6
Guerriero, 2017, Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages, Nature, 543, 428, 10.1038/nature21409
Ager, 2015, Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy, J Natl Cancer Inst, 107, 1, 10.1093/jnci/djv017
Dewan, 2012, Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer, Clin Cancer Res, 18, 6668, 10.1158/1078-0432.CCR-12-0984
Hudis, 2007, Trastuzumab-mechanism of action and use in clinical practice, New Engl J Med, 357, 39, 10.1056/NEJMra043186
Park, 2010, The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity, Cancer Cell, 18, 160, 10.1016/j.ccr.2010.06.014
Xu, 2012, The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody, Protein Cell, 3, 441, 10.1007/s13238-012-2044-3
Willingham, 2012, The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors, Proc Natl Acad Sci USA, 109, 6662, 10.1073/pnas.1121623109
Weiskopf, 2013, Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies, Science, 341, 88, 10.1126/science.1238856
Shi, 2015, Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages, J Immunol, 194, 4379, 10.4049/jimmunol.1402891
Zhao, 2011, CD47-signal regulatory protein-a (SIRPa) interactions form a barrier for antibody-mediated tumor cell destruction, Proc Natl Acad Sci USA, 108, 18342, 10.1073/pnas.1106550108
Xu, 2017, Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein α signaling, Immunity, 47, e5
Arlauckas, 2017, In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy, Sci Transl Med, 9, eaal3604, 10.1126/scitranslmed.aal3604
Gordon, 2017, PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity, Nature, 545, 495, 10.1038/nature22396
Zhu, 2014, CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models, Cancer Res, 74, 5057, 10.1158/0008-5472.CAN-13-3723
Beatty, 2011, CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans, Science, 331, 1612, 10.1126/science.1198443
Zippelius, 2015, Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment, Cancer Immunol Res, 3, 236, 10.1158/2326-6066.CIR-14-0226
Ma, 2017, Combination agonist and antagonist antibody therapy enhances vaccine induced T cell responses in non-immunogenic cancers, Cancer Res, 77, 10.1158/1538-7445.AM2017-2613
Bose, 2016, Imprime PGG treatment enhances antibody-dependent cellular phagocytosis (ADCP) of tumor cells by monocyte-derived macrophages. Cancer, Immunol Res, 4
Chan, 2014, Imprime PGG, a yeast β-glucan immunomodulator, has the potential to repolarize human monocyte-derived M2 macrophages to M1 phenotype, J Immunother Cancer, 2, 10.1186/2051-1426-2-S3-P191
Bose, 2017, Innate immune modulation: The novel immunotherapeutic Imprime PGG triggers the anti-cancer immunity cycle in concert with tumor-targeting, anti-angiogenic and checkpoint inhibitor antibodies. Cancer, Immunol Res, 5
Bendell, 2014, A phase 1 study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF1R), in patients with advanced or metastatic cancers, Mol Cancer Ther, 12
Ries, 2014, Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy, Cancer Cell, 25, 846, 10.1016/j.ccr.2014.05.016
Querfeld, 2017, A single direct intratumoral injection of TTI-621 (SIRPαFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: preliminary findings employing an immune checkpoint inhibitor blocking the CD47 “do not eat”, Blood, 130
Rüter, 2010, Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors, Cancer Biol Ther, 10, 983, 10.4161/cbt.10.10.13251
Vonderheide, 2007, Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody, J Clin Oncol, 25, 876, 10.1200/JCO.2006.08.3311
Thomas, 2017, A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer, Invest New Drugs, 35, 345, 10.1007/s10637-017-0450-3
Uhlik, 2018, Imprime PGG, a soluble yeast β-glucan PAMP, in combination with pembrolizumab induces infiltration and activation of both innate and adaptive immune cells within tumor sites in melanoma and triple-negative breast cancer (TNBC) patients, Proc Am Assoc Cancer Res
Adams, 2012, Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer, Clin Cancer Res, 18, 6748, 10.1158/1078-0432.CCR-12-1149
Vatner, 2013, Novel combination of toll-like receptor (TLR)-7 agonist imiquimod and local radiation therapy in the treatment of metastatic breast cancer involving the skin or chest wall, Int J Radiat Oncol Biol Phys, 87, 10.1016/j.ijrobp.2013.06.286
Geller, 2010, Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers, Cancer Immunol Immunother, 59, 1877, 10.1007/s00262-010-0914-1
Bonapace, 2014, Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis, Nature, 515, 130, 10.1038/nature13862
Lim, 2016, Targeting the CCL2-CCR2 signaling axis in cancer metastasis, Oncotarget, 7, 28697, 10.18632/oncotarget.7376
Diéras, 2015, Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study, Breast, 24, 182, 10.1016/j.breast.2014.11.003
Kaufman, 2014, A phase 1b study of trebananib plus paclitaxel (P) and trastuzumab (T) in patients (pts) with HER2+ locally recurrent or metastatic breast cancer (MBC), J Clin Oncol, 32, 10.1200/jco.2014.32.15_suppl.502
Allavena, 2005, Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production, Cancer Res, 65, 2964, 10.1158/0008-5472.CAN-04-4037
Goldstein, 2014, Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens, Clin Breast Cancer, 14, 396, 10.1016/j.clbc.2014.06.006
Blum, 2016, A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer, Breast Cancer Res Treat, 155, 295, 10.1007/s10549-015-3675-x
Rogers, 2011, Tumour macrophages as potential targets of bisphosphonates, J Transl Med, 9, 177, 10.1186/1479-5876-9-177
Brandão, 2013, A randomised controlled phase II trial of pre- operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer, Breast Cancer Res, 15, R29, 10.1186/bcr3409
Stasinopoulos, 2013, COX-2 in cancer: Gordian knot or Achilles heel?, Front Pharmacol, 4, 34, 10.3389/fphar.2013.00034
Wainberg, 2017, First-in-human phase 1 dose escalation and expansion of a novel combination, anti-CSF-1 receptor (cabiralizumab) plus anti-PD-1 (nivolumab), in patients with advanced solid tumors, J Immunother Cancer, 5
Krieg, 2018, High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy, Nat Med, 24, 144, 10.1038/nm.4466
Kumar, 2017, Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors, Cancer Cell, 32, e5
Neelapu, 2018, Chimeric antigen receptor T-cell therapy-assessment and management of toxicities, Nat Rev Clin Oncol, 15, 47, 10.1038/nrclinonc.2017.148
Blykers, 2015, PET Imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments, J Nucl Med, 56, 1265, 10.2967/jnumed.115.156828